cln-978
mAbexperimentalBi-specific
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 31, 2023 (NCT05879744)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CD3E activator
- B-lymphocyte antigen CD19BINDING AGENT
CD19 binding agent
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07041099 | Phase 1 | Oct 1, 2025 | Cullinan Therapeutics Inc. |
| NCT06994143 | Phase 1 | May 19, 2025 | Cullinan Therapeutics Inc. |
| NCT06613360 | Phase 1 | Nov 30, 2024 | Cullinan Therapeutics Inc. |
| NCT05879744 | Phase 1 | May 31, 2023 | Cullinan Oncology, LLC |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cullinan Therapeutics Inc. | For profit | 3 | 3 | 1 | 2024 |
| Cullinan Oncology, LLC | Academic/Hospital | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1